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Abstract
Background: The reduced expression of the Adenomatous polyposis coli (APC) gene, a tumor suppressor gene,
through promoter hypermethylation has been reported to play a key role in the carcinogenesis. However, the
correlation between APC promoter hypermethylation and ovarian cancer (OC) remains to be clarified.
Methods: A comprehensive literature search was carried out in related research databases. The overall odds
ratio (OR) and corresponding 95 % confidence interval (CI) were used to evaluate the effects of APC promoter
hypermethylation on OC and clinicopathological characteristics.
Results: Ultimately, 12 eligible studies were used in our study, including 806 OC samples, 429 normal controls, 109
benign lesions and 75 LMP samples. The pooled OR showed that APC promoter hypermethylation was significantly
higher in OC than in normal and benign controls (OR = 6.18 and OR = 3.26, respectively). No significant correlation
was observed between OC and low malignant potential (LMP) tumors (P = 0.436). In the comparison of OC and
normal controls, subgroup analysis based on race showed that the overall OR of APC promoter hypermethylation
was significant and similar in Asians and Caucasians (OR = 8.34 and OR = 5.39, respectively). A subgroup analysis
based on sample type found that the pooled OR was significantly higher in blood than in tissue (OR = 18.71 and
OR = 5.74, respectively). A significant association was not observed between APC promoter hypermethylation and
tumor grade or tumor stage. The pooled OR indicated that APC promoter hypermethylation was significantly lower
in serous carcinoma than in non-serous carcinoma (OR = 0.56, P = 0.02). No obvious publication bias was detected
by Egger’s test (all P > 0.05).
Conclusions: APC promoter hypermethylation may be linked to the increased risk of OC. It was associated with
histological type, but not with tumor grade or tumor stage. Moreover, hypermethylated APC may be a noninvasive
biomarker using blood samples. Future studies are required to validate these results.
Keywords: APC, Hypermethylation, Ovarian cancer, Serous carcinoma, Biomarker
Background
Ovarian cancer (OC) is the second most common gyneco-
logic cancer after cervical cancer and the most lethal gyne-
cologic cancer [1]. Based on cancer statistics, approximately
22,280 new cases are estimated in 2016 in the USA, leading
to 14,240 deaths due to OC [1]. Serous carcinoma is the
most common histotype of ovarian cancer and accounts for
the majority of deaths [2]. This is possibly due to the lack
of symptoms of early-stage disease and effective early detec-
tion methods; less than 20 % of ovarian cancer patients can
be diagnosed early [3]. The diagnosis of ovarian cancer is
frequently determined at an advanced stage and most pa-
tients are treated via surgery combined with chemotherapy
drugs [4]. The 5-year relative survival rate of ovarian cancer
patients is only 38 % [1].
Studies have proven that epigenetic modifications, includ-
ing DNA methylation, histone modifications, nucleosome
positioning and non-coding RNAs, are early and frequent
events in cancer [5, 6]. DNA methylation as a major mech-
anism of epigenetic modifications plays an important role
in carcinogenesis and cancer progression [7, 8]. Cancer is a
genetic disease that involves abnormalities of oncogenes
and/or tumor suppressor genes (TSGs) [9]. Aberrant DNA
methylation of CpG islands in the promoter regions leads
to the silencing of tumor suppressor genes in cancer [10,
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11]. The adenomatous polyposis coli (APC) gene is a tumor
suppressor gene located on chromosome 5q21 that encodes
a large multidomain protein [12]. The dysfunction of the
adenomatous polyposis coli (APC) protein participates in
tumorigenesis [13]. The APC gene has a major role in
WNT signaling, cell cycle regulation, cell differentiation
and proliferation, transcriptional activation, chromosomal
instability, and apoptosis [14–16].
However, an individual study with a small number of
subjects may lack strong statistical power. Thus, we sys-
tematically investigated studies of APC promoter hyper-
methylation and OC to evaluate the correlation between
APC promoter hypermethylation and OC. Moreover, we
also validated the clinicopathological significance of
hypermethylated APC in ovarian cancer.
Methods
Literature search
The relevant literature were found in the PubMed,
Embase, EBSCO, Cochrane Library, CNKI and Wanfang
databases without language limitations. The following
keywords or search terms were used: (adenomatous
polyposis coli OR APC) AND (ovarian OR ovary) AND
(cancer OR carcinoma OR tumor OR neoplasm) AND
(methylation OR epigene*), updated to March 21st, 2016.
Selection criteria
The eligible studies had to meet the following inclusion
criteria: 1) cancer patients were diagnosed as primary
ovarian carcinoma by histopathological examination; 2)
studies were associated with APC gene promoter methy-
lation and ovarian cancer; 3) the methylated APC gene
must have sufficient data about the frequencies of pro-
moter methylation to evaluate the correlation of APC
promoter methylation and ovarian cancer with clinico-
pathological features; 4) if the authors used duplicate
sample data and published more than one paper, only
the most recent paper or the most complete paper with
the larger sample size was applied. The excluded studies
did not meet the above inclusion criteria.
Data extraction
For the eligible studies included in the current meta-
analysis, the relevant information were extracted as fol-
lows: the first author’s surname, publication year, coun-
try, ethnic population, methylation detection method,
sample type, the number of APC promoter methylation
events, sample size, and clinicopathological characteris-
tics, such as tumor grade, tumor stage and tumor
histology. Benign lesions, normal samples and low ma-
lignant potential (LMP) tumors were defined as controls.
Moreover, tumor grades of ≤ 2 were defined as low-
grade, and a tumor grade of 3 was defined as high-grade.
Tumor stages of ≤ 2 were defined as early stage, while
tumor stages of 3–4 were defined as advanced stage.
Non-serous histotypes consisted of clear cell carcinoma
(CC), endometrioid carcinoma (EC), mucinous carcin-
oma (MC) or transitional cell carcinoma (TC).
Statistical analysis
The present study was performed using STATA software
(version 12.0, Stata Corporation, College Station, TX,
USA). The pooled odds ratio (OR) and corresponding
95 % confidence interval (95 % CI) were calculated and
summarized to assess the relationship between APC
promoter methylation and ovarian cancer. Heterogeneity
of eligible studies was evaluated based on Cochran’s Q
test and I2 statistic [17]. If I2 ≥ 50 % and p < 0.1, signifi-
cant heterogeneity was observed and a random-effects
model was used; otherwise, a fixed-effects model was
applied, indicating a lack of heterogeneity [18, 19].
Publication bias was detected using Egger’s linear regres-
sion test [20].
Results
The characteristics of included studies
Initially, we searched 94 potentially relevant articles
using the above databases and keywords. According to
the inclusion criteria, the final 12 studies that met the
selection criteria were included in the present meta-
analysis (Fig. 1). The methylation region was the
promoter. Among the 12 studies, only 1 study used
quantitative methylation specific PCR (QMSP) detection;
the others used the methylation specific PCR (MSP) test.
Twelve studies assessed the correlation between APC
promoter methylation and ovarian cancer, including 10
cancer-normal studies, 7 cancer-benign studies and 5
cancer-LMP studies. In addition, 8 studies evaluated the
association between APC promoter methylation and
clinicopathological features, including 4 studies of tumor
grade, 5 studies of tumor stage and 7 studies of tumor
histology. The basic characteristics of selected studies
were presented in Table 1 [21–32].
The association of APC promoter hypermethylation and
ovarian cancer
When cancer patients were compared to normal sam-
ples, benign lesions, and LMP patients, the fixed-effects
model was used in the current meta-analysis, indicating
a lack of heterogeneity (I2 = 0.0 %, P = 0.679; I2 = 0.0 %,
P = 0.938; I2 = 0.0 %, P = 0.663; respectively) (Table 2).
The results showed that the pooled OR of the APC
promoter hypermethylation was significantly higher in
ovarian cancer than in normal samples and benign le-
sions (OR = 6.18, 95 % CI = 4.02–9.51, P < 0.001; OR =
3.26, 95 % CI = 1.65–6.44, P = 0.001; respectively), in-
cluding 10 studies of 706 ovarian cancer patients and
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429 normal samples and 7 studies of 431 ovarian cancer
patients and 109 benign lesions (Figs. 2 and 3).
In the comparison of cancer and normal controls, sub-
group analyses based on race (Asians and Caucasians)
and sample type (tissue and blood) were performed to
assess the difference of a strong association. According
to the subgroup analysis of the ethnic population, the
result suggested that APC promoter hypermethylation
was significantly associated with Asians and Caucasians
(OR = 8.34, 95 % CI = 3.63–19.13, P < 0.001; OR = 5.39,
95 % CI = 3.25–8.94, P < 0.001; respectively). Subgroup
analysis based on sample type showed that the pooled
OR value was 18.71 (95 % CI, 2.41–145.20; P = 0.005) in
blood and 5.74 (95 % CI, 3.68–8.95; P < 0.001) in tissue,
indicating that the result was significantly associated
with different sample types.
In addition, when 319 cancer patients were compared
to 75 LMP patients from 5 studies, no significant
association was observed in our study (OR = 1.30, 95 %
CI = 0.67–2.51, P = 0.436) (Table 2).
The association of APC promoter hypermethylation with
clinicopathological features
We further analyzed the possible association between
APC promoter hypermethylation and clinicopathological
features. As shown in Table 2, there was statistically sig-
nificant heterogeneity in APC promoter hypermethyla-
tion in ovarian cancer in relation to tumor grade and
tumor stage (I2 = 68.5 %, P = 0.013; I2 = 61.0 %, P = 0.025;
respectively), using the random-effects model. No obvi-
ous heterogeneity was found in relation to tumor hist-
ology, thus, a fixed-effects model was used (I2 = 0.0 %
and P = 0.584).
The pooled OR from 4 studies involving 116 low-
grade ovarian cancer patients and 148 high-grade ovar-
ian cancer patients was shown in Table 2 (OR = 0.46,
95 % CI = 0.13–1.65, P = 0.233), suggesting that APC
promoter hypermethylation was not significantly associ-
ated with tumor grade. As shown in Table 2, our result
from 5 studies indicated that the correlation between
APC promoter hypermethylation and tumor stage was
not statistically significant (OR = 0.76, 95 % CI = 0.31–
1.88, P = 0.558), including 188 early ovarian cancer pa-
tients and 278 advanced ovarian cancer patients. The
overall OR from 7 studies including 193 serous carcin-
oma and 217 non-serous carcinoma cases suggested that
APC promoter hypermethylation was significantly
correlated with tumor histology (OR = 0.56, 95 % CI =
0.35–0.91, P = 0.02), and it was lower in serous carcin-
oma than in non-serous carcinoma (Fig. 4).
Publication bias
Egger’s linear regression test was performed to detect
the potential publication bias. The results of Egger’s test
on APC promoter hypermethylation indicated that there
was not obvious evidence of publication bias in the com-
parison of cancer and control groups, in relation to
tumor grade, tumor stage, and tumor histology in cancer
(all P > 0.05) (Table 2).
Discussion
The loss of gene expression associated with the CpG
islands of promoter methylation of different genes has
been found in many cancers [33–35]. The promoter
hypermethylation of tumor suppressor genes (TSG) in-
volving cell proliferation, cell death, cell migration, and
cell invasion leads to the initiation and development of
cancer [36]. APC promoter hypermethylation has been
reported in some cancers, including ovarian cancer,
which indicates that it can become a noninvasive bio-
marker for cancer detection [23, 37–39]. Although some
studies have been conducted to assess the frequency of
hypermethylation of the APC promoter in OC, the re-
sults were still inconsistent and controversial. For ex-
ample, Caceres et al. [29] found that the frequency of
APC promoter hypermethylation was 11.4 % in ovarian
cancer tissue. Tam et al. [27] found that frequency of
APC promoter hypermethylation was 47.2 % in ovarian
cancer tissue. Therefore, we utilized this meta-analysis
to identify the correlation between APC promoter hyper-
methylation and OC.
Fig. 1 Flow diagram of the literature search strategy to identify studies
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Table 1 The basic characteristics of the included studies
First author Country Ethnicity Method Sample Cancer LMP Benign Normal Low-grade High-grade StageI-II Stage III-IV Serous carcinoma Non-serous carcinoma
N (M %) N (M %) N (M %) N (M %) M/N M/N M/N M/N M/N M/N
Rathi 2002 [30] USA Caucasians MSP Tissue 49 (18.4) - 16 (0) - - - - - - -
Caceres 2004 [29] USA Caucasians MSP Tissue 35 (11.4) 10 (10) 10 (0) 10 (0) 0/12 4/23 1/8 3/27 2/21 2/14
Caceres 2004 [29] USA Caucasians MSP Blood 35 (8.6) 10 (10) 10 (0) 20 (0) 0/12 3/23 1/8 2/27 1/21 2/14
Makarla 2005 [28] USA Caucasians MSP Tissue 23 (21.7) 23 (0) 23 (0) 16 (0) - - - - 1/9 4/14
Tam 2007 [27] China Asians MSP Tissue 89 (47.2) 16 (50) 19 (26.3) 16 (25) - - - - - -
Wu 2007 [26] Norway Caucasians MSP Tissue 51 (23.5) 2 (0) 2 (0) - 7/26 5/23 9/25 3/26 3/19 9/27
Shen 2007 [31] China Asians MSP Tissue 63 (22.2) - - 30 (0) - - - - 4/34 10/29
Sun 2008 [32] China Asians MSP Tissue 59 (32.2) - - 42 (2.4) 5/36 14/23 2/21 17/38 11/30 8/29
Ho 2010 [25] China Asians MSP Tissue 63 (23.8) - 10 (0) 5 (0) - - - - 13/48 2/15
Bhagat 2012 [24] India Caucasians MSP Tissue 86 (29.1) 14 (28.6) 19 (15.8) 15 (0) 10/30 15/56 6/23 19/63 11/44 14/42
Zhang 2013 [23] China Asians MSP Blood 20 (35) - - 62 (0) - - - - - -
Brait 2013 [22] USA Caucasians QMSP Tissue 33 (15.1) - - 13 (0) - - - - - -
Al-Shabanah 2014 [21] Saudi Arabia Caucasians MSP Tissue 200 (36) - - 200 (10) - - 28/103 44/97 - -













Our findings supported that OC had a greater hyper-
methylation of APC promoter than benign lesions and
normal samples, suggesting that APC inactivation via
hypermethylation is involved in the carcinogenesis and
development of OC. However, the frequency of APC
promoter hypermethylation was similar in OC and LMP,
indicating that APC promoter hypermethylation could
not distinguish OC and LMP. Our results were credible
based on the lack of publication bias.
When cancer was compared to normal controls, sub-
group analysis of ethnicity showed that the pooled OR
from the Asian and Caucasian populations was similar,
Fig. 2 Forest plot for the association of APC promoter hypermethylation showing the pooled OR in cancer vs. normal controls
Table 2 Summary of the pooled OR
Studies Overall OR (95 % CI) I2; p P value Cases Controls p (Egger’s test)
Cancer vs. Normal 10 6.18 (4.02–9.51) 0.0 %; 0.679 <0.001 706 429 0.197
Subgroup
Sample type
Blood 2 18.71 (2.41–145.20) 39.6 %; 0.198 0.005 55 82
Tissue 9 5.74 (3.68–8.95) 0.0 %; 0.818 < 0.001 651 347
Race
Caucasians 5 5.39 (3.25–8.94) 0.0 %; 0.981 < 0.001 294 155
Asians 5 8.34 (3.63–19.13) 40.1 %; 0.154 < 0.001 567 274
Cancer vs. Benign 7 3.26 (1.65–6.44) 0.0 %; 0.938 0.001 431 109 0.172
Cancer vs. LMP 5 1.30 (0.67–2.51) 0.0 %; 0.663 0.436 319 75 0.199
Clinicopathological features Cancer patients
Low-grade High-grade
Tumor grade 4 0.46 (0.13–1.65) 68.5 %; 0.013 0.233 116 148 0.488
StageI-II Stage III-IV
Tumor stage 5 0.76 (0.31–1.88) 61.0 %; 0.025 0.558 188 278 0.449
Serous carcinoma Non-serous carcinoma
Tumor histology 7 0.56 (0.35–0.91) 0.0 %; 0.584 0.02 193 217 0.238
LMP low malignant potential tumor, OR odds ratio, 95 % CI 95 % confidence interval
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suggesting that Asian and Caucasian populations were
susceptible to APC promoter hypermethylation. Interest-
ingly, subgroup analysis of sample type indicated that
hypermethylated APC was significantly higher in blood
(OR = 18.71, P = 0.005) than in tissue (OR = 5.74, P <
0.001), which suggested that APC promoter hyper-
methylation may become a potential noninvasive bio-
marker based blood test for OC. However, the
results should be carefully considered as only two
studies with a small number of subjects were in-
cluded in the blood subgroup.
Next, the clinical significance of APC promoter hyper-
methylation was first determined in cancer. APC pro-
moter hypermethylation was not correlated with clinical
stage and tumor grade, but was associated with histo-
logical subtype in which it was significantly lower in
Fig. 4 Forest plot for the correlation of APC promoter hypermethylation showing the pooled OR in cancer in relation to tumor histotype
Fig. 3 Forest plot for the association of APC promoter hypermethylation showing the pooled OR in cancer vs. benign controls
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serous carcinoma than in non-serous carcinoma, indicat-
ing that APC promoter hypermethylation was correlated
with a decreased risk of serous carcinoma. Therefore,
APC promoter hypermethylation may be a potential
drug target for serous carcinoma.
The current study had several potential limitations.
First, although we searched the literature as completely
as possible, only articles published in English or Chinese
were selected, which may lead to selection bias. Second,
based on insufficient data and studies about other clini-
copathological features, such as age, lymph node status,
etc., the correlation between APC promoter hyperme-
thylation and other clinicopathological features was not
conducted in the present meta-analysis. Third, the inter-
pretation of the pooled OR of the blood subgroup with a
small sample size should be conservative. More studies
comprising larger sample sizes are necessary to confirm
our results.
Conclusion
In conclusion, the current findings revealed that APC
promoter hypermethylation may play a key role in the
initiation of OC. APC promoter hypermethylation de-
creased the risk of the serous carcinoma histotype.
Moreover, hypermethylated APC may be a potential
promising biomarker for the clinical screening of OC in
blood. Based on the limitations of the current sample
size, additional studies is very essential in the future.
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